acetaminophen and Injuries, Soft Tissue studies

Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.

Research Excerpts

Excerpt	Relevance	Reference
"There was no difference in analgesic effects or side effects observed using oral paracetamol, ibuprofen or a combination of both in patients with mild to moderate pain after soft tissue injuries attending the ED."	9.27	Oral paracetamol and/or ibuprofen for treating pain after soft tissue injuries: Single centre double-blind, randomised controlled clinical trial. ( Cattermole, GN; Graham, CA; Hung, KKC; Leung, LY; Leung, YK; Lo, RSL; Man, SY; Rainer, TH; Woo, WK, 2018)
"There was no difference in analgesic effects or side effects observed using oral paracetamol, ibuprofen or a combination of both in patients with mild to moderate pain after soft tissue injuries attending the ED."	5.27	Oral paracetamol and/or ibuprofen for treating pain after soft tissue injuries: Single centre double-blind, randomised controlled clinical trial. ( Cattermole, GN; Graham, CA; Hung, KKC; Leung, LY; Leung, YK; Lo, RSL; Man, SY; Rainer, TH; Woo, WK, 2018)
"Patients (N = 77, aged 8-14 y, 61% male) with ankle injuries presenting to a regional pediatric emergency department were assigned to receive either acetaminophen (15 mg/kg 4 times a day) or naproxen (5 mg/kg 4 times a day) in a double-blind fashion on a routine basis for a 5 day period."	5.12	Naproxen versus acetaminophen for therapy of soft tissue injuries to the ankle in children. ( Cukiernik, VA; Lim, R; Matsui, D; Rieder, MJ; Seabrook, JA; Warren, D, 2007)
" A 55-year-old female was admitted to the burn unit (West Penn Burn Center, Western Pennsylvania Hospital, Pittsburgh, PA) after she initially presented with infection and cellulitis to her bilateral upper extremities 3 weeks after intravenously injecting herself with crushed oxycodone/acetaminophen."	3.81	Subcutaneous Injection of Percocet: A Case of Severe Soft Tissue Loss. ( Aballay, AM; Abboud, C; Baskin, SM; Chen, W; Kelly, RW; Tolchin, E, 2015)
"Acute soft tissue injuries are common and costly."	2.66	Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. ( Dalziel, SR; Jones, P; Lamdin, R, 2020)
" The evidence was usually either low quality or very low quality, reflecting study limitations, indirectness such from as suboptimal dosing of single comparators, imprecision, or one or more of these."	2.52	Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. ( Dalziel, SR; Frampton, C; Jones, P; Lamdin, R; Miles-Chan, JL, 2015)
"Corticosteroid injections for tendon injuries may achieve a mild to moderate reduction in pain for up to 6 weeks."	2.43	The use of therapeutic medications for soft-tissue injuries in sports medicine. ( Orchard, JW; Paoloni, JA, 2005)
"Diclofenac was the NSAID of choice for 69."	1.30	Analgesia in soft-tissue injury: current practice in Auckland is not supported by the available evidence. ( Jones, PG, 1999)

Research

Studies (13)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Change From Baseline at Day 3 in Pain Visual Analog Scale (VAS) - Per Protocol Population

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (15.38)	18.2507
2000's	2 (15.38)	29.6817
2010's	5 (38.46)	24.3611
2020's	4 (30.77)	2.80

Authors	Studies
Clebak, KT	1
Weaver, LK	1
Croad, JR	1
Jones, P	2
Lamdin, R	2
Dalziel, SR	2
Yalçınlı, S	1
Kıyan, GS	1
Can, Ö	1
Kirschner, J	1
Hunter, B	1
Hung, KKC	1
Graham, CA	1
Lo, RSL	1
Leung, YK	1
Leung, LY	1
Man, SY	1
Woo, WK	1
Cattermole, GN	1
Rainer, TH	1
Miles-Chan, JL	1
Frampton, C	1
Baskin, SM	1
Abboud, C	1
Chen, W	1
Tolchin, E	1
Kelly, RW	1
Aballay, AM	1
Whitehead, PB	1
Mehendale, HM	1
Paoloni, JA	1
Orchard, JW	1
Cukiernik, VA	1
Lim, R	1
Warren, D	1
Seabrook, JA	1
Matsui, D	1
Rieder, MJ	1
Tuter, NV	1
Danilov, AB	1
Poliakova, LV	1
Jones, PG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double-Blind, 7-Day Study of the Efficacy and Safety of Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome[NCT00140933]	Phase 3	274 participants	Interventional	2003-04-30	Terminated
Efficacy and Security of Combined Analgesia (Opioid and Anti-inflammatory Agent) to Control Pain in Children Seen in the Emergency Department for a Trauma of a Limb[NCT01189773]	Phase 4	200 participants (Actual)	Interventional	2008-02-29	Completed
An Open Label Randomized Multicenter Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain[NCT00446797]	Phase 4	278 participants (Actual)	Interventional	2007-05-31	Completed
Ibuprofen Versus Acetaminophen vs Their Combination in the Relief of Musculoskeletal Pain in the Emergency Setting[NCT01827475]	Phase 2	90 participants (Actual)	Interventional	2010-07-31	Completed
The Efficacy and Safety of Administration of the COX-2 Selective NSAID, Etoricoxib (120mg od. for 7 Days) Compared to Diclofenac (50 mg Tds. for 7 Days) and Placebo as Adjunct Treatment in the First 7 Days of Treatment of Acute Grade II Lateral Ankle Liga[NCT00954785]	Phase 4	0 participants (Actual)	Interventional	2009-11-30	Withdrawn (stopped due to The study was terminated by Merck USA. The company did not supply drugs for the study.)
Cost-effectiveness Analysis of Oral Paracetamol and Ibuprofen for Treating Pain After Soft Tissue Limb Injuries: Double-blind, Randomised Controlled Trial[NCT00528658]	Phase 2	782 participants (Actual)	Interventional	2005-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Assessment of ankle pain by VAS: 100 mm horizontal line with left end being No Pain & right end being Worst Possible Pain. Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle. Distance from left end of line to mark. Change: mean score at day 3 minus mean score at baseline" (NCT00446797)
Timeframe: Baseline and day 3

Change From Baseline in Pain Visual Analog Scale (VAS) - Modified Intent to Treat Population

Intervention	scores on a scale (Mean)
Celecoxib	-44.88
nsNSAIDs	-40.76

"Assessment of ankle pain by VAS: 100 mm horizontal line, left end being No Pain & right end being Worst Possible Pain. Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle. Distance from left end of line to mark. Change: mean score at observation minus mean score at baseline" (NCT00446797)
Timeframe: Baseline and days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Index

Intervention	scores on a scale (Mean)
	Day 2	Day 3	Day 7
Celecoxib	-29.25	-44.87	-61.17
nsNSAIDs	-25.98	-40.75	-57.89

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~The pain interference index is the average of pain interference questions 5A to 5G. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5A

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	4.07	2.79	1.28
nsNSAIDs	4.01	2.83	1.33

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5A: Subject response to 'how, during the past 24 hours, pain has interfered with your general activity. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5B

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	5.40	3.65	1.78
nsNSAIDs	5.37	4.07	1.90

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5B: Subject response to 'how, during the past 24 hours, pain has interfered with your mood'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5C

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	3.72	2.43	1.17
nsNSAIDs	3.64	2.38	1.26

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5C: Subject response to 'how, during the past 24 hours, pain has interfered with your walking ability'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5D

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	5.10	3.58	1.65
nsNSAIDs	5.11	3.69	1.62

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5D: Subject response to 'how, during the past 24 hours, pain has interfered with your normal work (work outside the home and housework)'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5E

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	5.29	4.04	1.84
nsNSAIDs	5.39	4.04	1.87

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5E: Subject response to 'how, during the past 24 hours, pain has interfered with your relations with other people'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5F

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	2.70	1.81	0.80
nsNSAIDs	2.67	1.69	0.78

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5F: Subject response to 'how, during the past 24 hours, pain has interfered with your sleep'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5G

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	2.97	1.90	0.68
nsNSAIDs	2.87	1.86	0.82

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q5G: Subject response to 'how, during the past 24 hours, pain has interfered with your enjoyment of life'. Scale: 0 = does not interfere to 10 = completely interferes" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Index

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	3.33	2.13	1.07
nsNSAIDs	2.99	2.06	1.10

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Pain severity index is the average of the pain severity questions 1 to 4. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 1

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	4.24	2.84	1.37
nsNSAIDs	4.48	3.26	1.68

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q1: Subject response to 'describe your pain at its worst in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 1, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 2

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	5.71	3.81	2.08
nsNSAIDs	5.90	4.44	2.38

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q2: Subject response to 'describe your pain at its least in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 3

Intervention	scores on a scale (Mean)
	Day 2 (N = 133, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	3.25	2.07	0.83
nsNSAIDs	3.36	2.40	1.16

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q3: Subject response to 'describe your pain on the average'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7

Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 4

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N = 135, 131)	Day 7 (N = 133, 125)
Celecoxib	4.34	2.90	1.41
nsNSAIDs	4.41	3.26	1.74

"m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.~Q4: Subject response to 'how much pain you have right now'. Scale: 0 = no pain to 10 = pain as bad as you can imagine" (NCT00446797)
Timeframe: Days 2, 3 and 7

Number of Subjects Responding (Improving) - MITT Population

Intervention	scores on a scale (Mean)
	Day 2 (N = 134, 133)	Day 3 (N =135, 131)	Day 7 (N = 133, 125)
Celecoxib	3.64	2.58	1.14
nsNSAIDs	4.23	2.92	1.43

The number of subjects showing a response: a decrease of at least 20 mm (that is improvement) on the pain visual analog scale (VAS) scale (NCT00446797)
Timeframe: Days 2, 3 and 7

Pain Relief - MITT Population

Intervention	participants (Number)
	Day 2 - response (N=134, 133)	Day 2 - no response	Day 3 - response (N=135, 131)	Day 3 - no response	Day 7 - response (N=133, 125)	Day 7 - no response
Celecoxib	91	43	124	11	129	4
nsNSAIDs	79	54	116	15	120	5

"Subject's response to the statement My relief from starting pain is. Scale from 0 = None to 4 = Complete." (NCT00446797)
Timeframe: Days 2, 3 and 7

Physician Global Assessment of Ankle Injury

Intervention	participants (Number)
	Day 2 - None (N=135, 132)	Day 2 - A little	Day 2 - Some	Day 2 - A lot	Day 2 -Complete	Day 3 - None (N=135, 131)	Day 3 - A little	Day 3 - Some	Day 3 - A lot	Day 3 -Complete	Day 7 - None (N=133, 125)	Day 7 - A little	Day 7 - Some	Day 7 - A lot	Day 7 -Complete
Celecoxib	8	25	49	52	1	0	15	33	84	3	1	6	7	77	42
nsNSAIDs	5	33	52	42	0	1	21	46	60	3	1	3	15	80	26

Investigator evaluation of overall severity of ankle injury. Scale: 5 point from 1 = Very mild (very mild signs and symptoms of ankle sprain) to 5 =Very severe (very severe signs and symptoms of ankle sprain) (NCT00446797)
Timeframe: Days 3 and 7

Subject Assessment of Normal Function / Activity

Intervention	participants (Number)
	Day 3 - very mild (N=134, 131)	Day 3 - mild	Day 3 - moderate	Day 3 - severe	Day 3 - very severe	Day 7 - very mild (N=132, 125)	Day 7 - mild	Day 7 - moderate	Day 7 - severe	Day 7 - very severe
Celecoxib	20	71	40	2	1	87	38	7	0	0
nsNSAIDs	12	79	38	2	0	70	47	7	1	0

"Subject response to question: How does your ankle injury affect your walking and normal activity? Scale from 1 = Normal walking/activity and no pain to 5 = Severely restricted walking due to pain and can't resume normal activities (normal activities defined as all activity that a subject did on a routine basis, including work and recreation)" (NCT00446797)
Timeframe: Days 2, 3 and 7

Subject's Global Assessment of Ankle Injury

Intervention	participants (Number)
	Day 2 - normal no pain (N =135, 133)	Day 2 - normal with pain	Day 2 - mildly restricted	Day 2 - moderately restricted	Day 2 - severely restricted	Day 3 - normal no pain (N = 135, 131)	Day 3 - normal with pain	Day 3 - mildly restricted	Day 3 - moderately restricted	Day 3 - severely restricted	Day 7 - normal no pain (N = 133, 125)	Day 7 - normal with pain	Day 7 - mildly restricted	Day 7 - moderately restricted	Day 7 - severely restricted
Celecoxib	5	40	59	19	12	18	52	49	14	2	62	55	11	4	1
nsNSAIDs	2	30	55	39	7	13	46	57	11	4	43	68	8	3	3

"Subject response to question: Considering all the ways your ankle injury affects you, how are you doing today? Scale: 5 point from 1 = very good (no symptoms and no limitation of normal activities) to 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities)." (NCT00446797)
Timeframe: Days 2, 3 and 7

Need for Rescue Pain Relief

Pain Severity

Intervention	participants (Number)
	Day 2 - Very good (no symptoms) (N=135, 133)	Day 2 - Good (mild symptoms)	Day 2 - Fair (moderate symptoms)	Day 2 - Poor (severe symptoms)	Day 2- Very poor (very severe symptoms)	Day 3 - Very good (no symptoms) (N=135, 131)	Day 3 - Good (mild symptoms)	Day 3 - Fair (moderate symptoms)	Day 3 - Poor (severe symptoms)	Day 3 - Very poor (very severe symptoms)	Day 7 - Very good (no symptoms) (N=133, 125)	Day 7 - Good (mild symptoms)	Day 7 - Fair (moderate symptoms)	Day 7 - Poor (severe symptoms)	Day 7 - Very poor (very severe symptoms)
Celecoxib	1	40	76	17	1	8	68	54	5	0	53	61	17	2	0
nsNSAIDs	1	31	80	19	2	6	55	63	7	0	37	63	21	4	0

Intervention	participants (Number)
Ibuprofen	11
Acetaminophen	10
Ibuprofen-acetaminophen Combination	5

Pain score on 100 mm VAS from 0 (no pain) to 100 (worst pain) (NCT01827475)
Timeframe: 1 hour

Article	Year
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2020, 08-12, Volume: 8 Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Anti-Infl	2020
Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. The Cochrane database of systematic reviews, 2015, Jul-01, Issue:7 Topics: Acetaminophen; Acute Disease; Administration, Oral; Analgesics; Analgesics, Opioid; Anti-Inflammator	2015
Oral NSAIDs versus other oral analgesic agents for acute soft tissue injury. International journal of evidence-based healthcare, 2016, Volume: 14, Issue:3 Topics: Acetaminophen; Administration, Oral; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-S	2016
Once initiated, how does toxic tissue injury expand? Trends in pharmacological sciences, 2012, Volume: 33, Issue:4 Topics: Acetaminophen; Animals; Calpain; Cell Death; Disease Progression; Free Radicals; Humans; Soft Tissue	2012
The use of therapeutic medications for soft-tissue injuries in sports medicine. The Medical journal of Australia, 2005, Oct-03, Volume: 183, Issue:7 Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster	2005

Article	Year
Comparison of intravenous ibuprofen and paracetamol efficiency in soft tissue injuries: A randomized, double-blind study. The American journal of emergency medicine, 2020, Volume: 38, Issue:10 Topics: Acetaminophen; Administration, Intravenous; Adolescent; Adult; Analgesics; Double-Blind Method; Emer	2020
Oral paracetamol and/or ibuprofen for treating pain after soft tissue injuries: Single centre double-blind, randomised controlled clinical trial. PloS one, 2018, Volume: 13, Issue:2 Topics: Acetaminophen; Administration, Oral; Analgesics; Double-Blind Method; Female; Humans; Ibuprofen; Inf	2018
Naproxen versus acetaminophen for therapy of soft tissue injuries to the ankle in children. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:9 Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Ankle Injuries; Anti-Inflammatory Agents, Non-S	2007

Article	Year
Oral NSAIDs vs. Other Oral Analgesic Agents for Acute Soft Tissue Injury. American family physician, 2023, Volume: 107, Issue:1 Topics: Acetaminophen; Administration, Oral; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Humans; So	2023
In acute soft tissue injuries, NSAIDs do not differ from acetaminophen for pain reduction. Annals of internal medicine, 2020, 12-15, Volume: 173, Issue:12 Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Humans; Pain; Pharmaceutical Pre	2020
Subcutaneous Injection of Percocet: A Case of Severe Soft Tissue Loss. Wounds : a compendium of clinical research and practice, 2015, Volume: 27, Issue:7 Topics: Acetaminophen; Analgesics, Non-Narcotic; Cellulitis; Debridement; Drug Combinations; Drug Eruptions;	2015
[The treatment of a complex regional pain syndrome]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 1997, Volume: 97, Issue:11 Topics: Acetaminophen; Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Caffeine; Cerebro	1997
Analgesia in soft-tissue injury: current practice in Auckland is not supported by the available evidence. The New Zealand medical journal, 1999, Oct-08, Volume: 112, Issue:1097 Topics: Acetaminophen; Adult; Analgesia; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal;	1999

acetaminophen and Injuries, Soft Tissue